SavedAdd your journal

Journals / Düzce Tıp Fakültesi Dergisi / 2020 / Cilt: 22 - Sayı: 3

Serum Uric Acid Level and Cardiovascular Disease Development Risk in Stage 3-5 Chronic Kidney Disease Patients

Evre 3-5 Kronik Böbrek Hastalarında Serum Ürik Asit Seviyesi ve Kardiyovasküler Hastalık Gelişim Riski

Suleyman KARAKOSE
Pages
171–174
Publication Date
2020-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patients were divided into two groups according to average serum uric acid levels;

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The patients with chronic kidney disease (CKD) have higher risk of cardiovascular disease (CVD) than the general population and this risk increases in advanced CKD stages.
📊
Key Findings & Data:The data about the association between CVD and uric acid level in stage 3-5 CKD patients are limited in the literature.
💡
Conclusion & Impact:The patients were divided into two groups according to average serum uric acid levels;
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Hiperürisemi · kronik böbrek hastalığı · kardiyovasküler hastalık

Abstract

Aim: The patients with chronic kidney disease (CKD) have higher risk of cardiovascular disease (CVD) than the general population and this risk increases in advanced CKD stages. The data about the association between CVD and uric acid level in stage 3-5 CKD patients are limited in the literature. The aim of this study is to investigate whether uric acid levels are associated with cardiovascular events and mortality in the CKD patients. Material and Methods: Patients who were followed up with the diagnosis of stage 3-5 CKD between June 2014 and December 2019 were evaluated retrospectively. A hundred stage 3-5 CKD cases above the age of eighteen were included in the study. The patients were divided into two groups according to average serum uric acid levels;

Özet

Amaç: Kronik böbrek hastalığı (KBH) olanlarda kardiyovasküler hastalık (KVH) riski genel popülasyondan daha yüksektir ve bu risk ileri KBH evrelerinde artmaktadır. Evre 3-5 KBH hastalarında KVH ve ürik asit seviyesi arasındaki ilişki hakkındaki veriler literatürde sınırlıdır. Bu çalışmanın amacı, KBH hastalarında ürik asit düzeyinin kardiyovasküler olaylar ve mortalite ile ilişkili olup olmadığının incelenmesidir. Gereç ve Yöntemler: Haziran 2014 ve Aralık 2019 tarihleri arasında evre 3-5 KBH tanısı ile takip edilen hastalar geriye dönük olarak değerlendirildi. On sekiz yaş üstü 100 evre 3-5 KBH olgusu çalışmaya dahil edildi. Hastalar ortalama serum ürik asit düzeylerine göre

🔖

Cite This Article

KARAKOSE, S. (2020). Serum Uric Acid Level and Cardiovascular Disease Development Risk in Stage 3-5 Chronic Kidney Disease Patients. Düzce Tıp Fakültesi Dergisi, Cilt: 22 - Sayı: 3, 171–174. https://ajindex.com/articles/420112

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Kasahara M, Kuwabara Y, Moriyama T, Tanabe K, Satoh-Asahara N, Katsuya T, et al. Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial. Clin Exp Nephrol. 2020;24(3):235-41.
  2. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91(1):227-34. Vásquez-Vivar J, Santos AM, Junqueira VB, Augusto O. Peroxynitrite-mediated formation of free radicals in human plasma: EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J. 1996;314(Pt 3):869-76. Emmerson BT. Atherosclerosis and urate metabolism. Aust N Z J Med. 1979;9(4):451-4.
  3. Ginsberg MH, Kozin F, O’Malley M, McCarty DJ. Release of platelet constituents by monosodium urate crystals. J Clin Invest. 1977;60(5):999-1007.
  4. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18(5):858-65.
  5. Liese AD, Hense HW, Löwel H, Döring A, Tietze M, Keil U. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases. Epidemiology 1999;10(4):391-7.
  6. Bengtsson C, Lapidus L, Stendahl C, Waldenström J. Hyperuricaemia and risk of cardiovascular disease and overall death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Acta Med Scand 1988;224(6):549-55.
  7. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404-10.
  8. Casiglia E, Spolaore P, Ginocchio G, Colangeli G, Di Menza G, Marchioro M, et al. Predictors of mortality in very old subjects aged 80 years or over. Eur J Epidemiol 1993;9(6):577-86.
  9. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart. 1997;78(2):147-53.
  10. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol. 2000;10(3):136-43.
  11. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131(1):7-